First implantation of resorbable antibacterial envelope announced
The debut implantation of a resorbable antibacterial envelope has been revealed.
The first ever implantation of a fully resorbable antibacterial envelope has taken place to help ensure surgery patients are at a lower risk of infection.
According to TYRX, the AIGISRx R antibacterial envelope is designed to stabilise electronic implantable devices such as pacemakers and defibrillators.
As well as this, the antibacterial envelope releases the antimicrobial agents rifampin and minocycline to help protect against microbial colonisation of the device during surgical implantation.
Cardiac electrophysiologist at the Quebec Heart and Lung Institute Dr Francois Philippon said: "I found implantation of the fully resorbable envelope to be very straightforward and believe that the combination of stabilisation and locally delivered antibiotics provided by the product will be of great potential benefit to our patients."
Indeed, Dr Philippon claims surgical site infections are on the increase and can cause patients to spend more time in hospital as they get treatment for the infection, which also puts them at greater risk of fatality.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...